Total revenue and other income nearly doubled (€2,4 million, +95%)R&D progress across the board, including initiation of the 4-arm Phase 2 clinical trial for AlenuraTM, targeting IC/BPS, a condition affecting at least 6 million U.S. patientsPDUFA goal date for Maxigesic® IV set for 17 October 2023 by the U.S. FDA1Evaluating external product candidates & advancing internal projects to reach 30 key assets before 2025Multiple NDA2 submissions expected within the next 18 monthsAnalyzing different go
Potential first-line treatment for interstitial cystitis/bladder pain syndrome (IC/BPS)Global opportunity with a patient population of at least 6 million in the U.S. alone1 Liège, Belgium – 22 June 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of Al
56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated Information – Inside Information - Liège, Belgium – 13 June 2023 – 6PM CET - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces the approval of all resolutions proposed at its Annual General Meeting (AGM) held at i